Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

Radiotherapy 30Temozolomide 16Carboplatin 16Chemotherapy, Adjuvant 15Cisplatin 13Vincristine 12Magnetic Resonance Spectroscopy 12Cyclophosphamide 11Etoposide 10Carmustine 10Methotrexate 8Specimen Handling 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 7X-Rays 6Thiotepa 6Surgical Procedures, Operative 6Phantoms, Imaging 6O(6)-benzylguanine 6Lomustine 6Biopsy 6motexafin gadolinium 4Nuclear Medicine Department, Hospital 4Drug Therapy 4Tamoxifen 3Psychiatric Rehabilitation 3Procarbazine 3Neoadjuvant Therapy 3Mental Status and Dementia Tests 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Central Nervous System Neoplasms × talazoparib × Clear all
NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

National Cancer Institute (NCI)

Phase 1/2 Completed
40 enrolled 32 charts
CNS

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡